期刊文献+

肿瘤血管生成的PET检测 被引量:3

PET imaging for evaluating tumor angiogenesis
原文传递
导出
摘要 肿瘤血管生成作为肿瘤的主要特征,在肿瘤生长和转移中起着重要作用,为肿瘤治疗提供了新策略。通过标记血管生成相关的受体、多肽、激酶或细胞外基质蛋白,形成高亲和力的分子探针,与肿瘤血管生成过程中产生的特异性靶分子结合,从而显示包括整合素、VEGF/VEGFR、基质金属蛋白酶(MMPs)等与血管生成关系密切的特征性血管生成因子,可从分子水平对肿瘤新生血管及血管靶向治疗疗效进行无创性检测。笔者就肿瘤血管生成PET影像学检测研究进展及未来发展作一综述。 Angiogenesis, a main characteristic in tumors, plays an important role in tumor growth and metastasis, which provides a new strategy for tumor treatment. By marking angiogenesis-related recep- tors, polypeptides, kinases or extracellular matrix proteins as high affinity molecular probes, PET imaging can noninvasively display integrins, VEGF/VEGFR, matrix metalloproteinases (MMPs) and closely moni- tor tumor angiogenesis and vascular-targeted treatments on the molecular level. In this paper, research pro- gress and future development of PET imaging for evaluating tumor angiogenesis are reviewed.
出处 《中华核医学与分子影像杂志》 CSCD 北大核心 2012年第6期478-480,共3页 Chinese Journal of Nuclear Medicine and Molecular Imaging
关键词 肿瘤 新生血管化 体层摄影术 发射型计算机 发展趋势 Neoplasms Neovaseularization Tomography, emission-computed Trends
  • 相关文献

参考文献26

  • 1Xiong JP, Stehle T, Zhang R, et al. Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science, 2002, 296: 151-155.
  • 2Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin αvβ3 antagonism. Anti cancer Agents Med Chem, 2006, 6: 407- 428.
  • 3Haubner R, Finsinger D, Kessler H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew Chem Int Ed Engl, 1997, 36: 1374-1389.
  • 4van Hagen PM, Breeman WA, Bernard HF, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer, 2000, 90: 186-198.
  • 5Haubner R, Weber WA, Beer A J, et al. Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [^18F] Galacto-RGD. PLoS Med, 2005, 2 : e70.
  • 6Beer AJ, Haubner R, Goebel M, et al. Biodistribution and pharmacokinetics of the αvβ3 -selective tracer ^18F-galacto-RGD in cancer patients. J Nucl Med, 2005, 46: 1333-1341.
  • 7Beer A J, Haubner R, Wolf I, et al. PET-based human dosimetry of ^18F-galacto-RGD, a new radiotracer for imaging αvβ3 expression. J Nucl Med, 2006, 47: 763-769.
  • 8Beer AJ, Grosu AL, Carlsen J, et al. [^18F] galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res, 2007, 13: 6610-6616.
  • 9Beer AJ, Lorenzen S, Metz S, et al. Comparison of integrin αvβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using ^18F-galacto-RGD and ^18F- FDG. J Nucl Med, 2008, 49: 22-29.
  • 10Boturyn D, Coll JL, Garanger E, et al. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J Am Chem Soc, 2004, 126 : 5730-5739.

同被引文献29

  • 1付彤,王峰,立彦,邱樊,章英剑,王明伟,邵国强,曹艳,张乐乐.99Tcm-3P-RGD2用于肺癌整合素αv β3表达水平检测的实验研究[J].中华核医学与分子影像杂志,2013,33(6). 被引量:5
  • 2刘昭飞,贾兵,史继云,杨志,赵慧云,王凡.^(99)Tc^m-RGD环肽二聚体的制备及其体内外评价[J].中华核医学杂志,2007,27(4):205-209. 被引量:18
  • 3Zhang K, Chen W, Zhang Y, et al. An anti-human CD13 mono- clonal antibody that suppresses the suppressive function of Treg cells [ J ]. Monoclon Antib Immunodiagn Immunother, 2013, 32 : 16-20.
  • 4Luan Y, Xu W. The structure and main functions of aminopeptid- ase N[J]. Curr Med Chem, 2007, 14: 639-647.
  • 5Ito S, Miyahara R, Takahashi R, et al. Stromal aminopeptidase N expression: correlation with angiogenesis in non-small-cell lung cancer[J]. Gen Thorac Cardiovasc Surg, 2009, 57: 591-598.
  • 6Dreischaltick J, Schwtippe C, Spieker T, et al. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile [ J ]. Int J Oncol, 2010, 37: 1389-1397.
  • 7Luo LM, Huang Y, Zhao BX, et al. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclita- xel[J]. Biomaterials, 2013, 34: 1102-1114.
  • 8Zucali PA, Simonelli M, De Vincenzo F, et al. Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours[ J]. Br J Cancer, 2013, 108: 58-63.
  • 9Meng J, Yan Z, Wu Y, et al. Preclinical safety evaluation of IFN alpha2a-NGR[J]. Regul Toxicol Pharmacol, 2008, 50: 294-302.
  • 10Santoro A, Pressiani T, Citterio G, et al. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma [ J 1. Br J Cancer, 2010, 103: 837-844.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部